AVENUE THERAPEUTICS, INC. (ATXI): Nasdaq/NYSE listing notice — Avenue Therapeutics receives Nasdaq delisting notice for bid price below $1.00 for 30 consecutive days

AVENUE THERAPEUTICS, INC.

Received Nasdaq notice on Sept 27, 2023 for non-compliance with minimum bid price requirement (Rule 5550(a)(2)).
Common stock closed below $1.00 per share for 30 consecutive business days.
Company has 180-day grace period through March 25, 2024 to regain compliance by closing at $1.00+ for 10+ consecutive days.
If not compliant by March 25, 2024, may seek second 180-day period if it meets initial listing criteria and intends to reverse split.
Company will monitor bid price and consider options; no assurance of maintaining listing.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

AVENUE THERAPEUTICS, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

September 27, 2023, Avenue Therapeutics, Inc. (the “ Company ”) received a letter from the Staff of the Listing Qualifications Department (the “ Staff ”) of The Nasdaq Stock Market LLC (“ Nasdaq ”) stating that the bid price of the Company’s common stock (“ Common Stock ”) had closed below $1.00 per share for 30 consecutive business days, and that, therefore, the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2) (the “ Minimum-Bid Price Requirement ”), which sets forth the minimum bid price requirement for continued listing on The Nasdaq Capital Market. Nasdaq’s notice has no i

View on SEC.gov

Browse all listing & compliance notices →

AVENUE THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001104659-23-104769

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.